It is currently Sun Nov 23, 2014 7:54 pm

News News of Gilenya

Site map of Gilenya » Forum : Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

About to start

This is much of a post on another forum. Please forgive me if you read it twice.


I took Copaxone EOD for the past year or so. It was not what was recommended by the doc but I just decided that every day was just too much. Of course, if I had believed Copax would make a huge difference I would have felt differentlly. But for 30% reduction in relapses... I figured I would take ...
Read more : About to start | Views : 893 | Replies : 5


immune compromised?

i was reading about the mechanism by which gilenya works-- trapping white blood cells in the lymph nodes. also that gilenya reduces your ability to fight infections... does this mean that if i take gilenya i am immune compromised? has anyone had a problem with infections, colds, or viruses increasing after taking gilenya?
Read more : immune compromised? | Views : 1363 | Replies : 5


Patient taking oral MS medication Gilenya developed PML

A patient taking Novartis' multiple sclerosis pill Gilenya developed a rare and potentially fatal viral disease, the Swiss drugmaker said on Tuesday, an unexpected setback as it faces growing competition from new oral treatments.

Gilenya is one of Novartis' big new drug hopes, growing 66 percent in the second quarter to $468 million. But the drug faces competition from new medicines such as Biogen Idec's Tecfidera....... Read More - http://www.ms-uk.org/index.cfm/gilenya
Read more : Patient taking oral MS medication Gilenya developed PML | Views : 1696 | Replies : 6


passed Gilenya screening waiting for appointment

Hi,

At our last conversation in March, my neurologist opened up the universe of MS drugs for me to choose one, including Tysabri.
That was a surprise. I had been gritting my teeth getting ready to reluctantly submit to Avonex. I took a week to think. I read trial results for Gilenya, especially the brain atrophy result and decided to add Gilenya while I can still afford health insurance. If it goes poorly I can ...
Read more : passed Gilenya screening waiting for appointment | Views : 1493 | Replies : 4


MS Drug Takes a Feisty Approach Aimed at Younger Patients

An MS Drug Takes a Feisty Approach Aimed at Younger Patients

The Swiss drug maker Novartis is taking a sassy new tack to win converts to its oral multiple sclerosis treatment, Gilenya. Its “Hey MS, Take This!” campaign shows patients sticking out their tongues with Gilenya capsules on them to show their willingness to fight back against the neurological condition..... Read More - http://www.ms-uk.org/index.cfm/MSnews
Read more : MS Drug Takes a Feisty Approach Aimed at Younger Patients | Views : 1185 | Replies : 0


Gilenya® Demonstrates Consistent Benefits..........

Gilenya® Demonstrates Consistent Benefits In Reduction Of Relapses And Brain Volume Loss In Relapsing-Remitting MS

Data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first and only once-daily oral therapy reimbursed to treat highly active relapsing-remitting multiple sclerosis (RRMS), significantly and consistently reduced the rate of brain volume loss and reduced relapse rates compared to interferon beta-1a IM or placebo.

The new data add to the ...
Read more : Gilenya® Demonstrates Consistent Benefits.......... | Views : 1156 | Replies : 0


Oral MS drug, Gilenya, Slowed Brain Loss in Study

Novartis AG said its Gilenya drug to treat multiple sclerosis helped slow brain loss, a measure linked to the severity of the disease.

Patients taking Gilenya in three large Novartis-led studies lost a third less brain volume than patients taking either a placebo or Biogen Idec Inc. Avonex, Novartis said in an e- mailed statement today..... Read More - http://www.ms-uk.org/index.cfm/gilenya
Read more : Oral MS drug, Gilenya, Slowed Brain Loss in Study | Views : 1024 | Replies : 0


Novartis To Present New Data On Multiple Sclerosis Treatment

Novartis AG said it will present new data on Multiple Sclerosis or MS treatment at the 65th annual meeting of the American Academy of Neurology or AAN.

It will highlight growing clinical trial and real-world experience with Gilenya (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS or RMS. Updates on studies of Gilenya in people with primary-progressive MS or PPMS and the investigational agent BAF312 (siponimod) in people with secondary-progressive ...
Read more : Novartis To Present New Data On Multiple Sclerosis Treatment | Views : 1517 | Replies : 0


MS-UK Gilenya Diaries

MS-UK Gilenya Diaries

Dan has sent in a new entry for his Gilenya Blog

You can read it at http://www.ms-uk.org/index.cfm/gilenyadan
Read more : MS-UK Gilenya Diaries | Views : 2775 | Replies : 16


Gilenya rebound

It may be harder stopping fingolimod (Gilenya) than starting it
http://www.overcomingmultiplesclerosis. ... arting+it/

Neurologists from Florence in Italy have reported the histories of a series of six people with MS who had to stop fingolimod (Gilenya) treatment for MS. All commenced an alternative disease-modifying drug when stopping, however within three months of stopping, five returned to pre-treatment levels of disease activity, and one experienced a rebound, that is the ...
Read more : Gilenya rebound | Views : 1711 | Replies : 2


 

Login  •  Register


Statistics

Total posts 221713 • Total topics 23018 • Total members 14544


Contact us | Terms of Service